Navigation Links
Drug Combos Effective Against Rheumatoid Arthritis
Date:11/26/2007

Older and newer medicine together often bring relief, study finds

MONDAY, Nov. 26 (HealthDay News) -- Combining an older synthetic drug with a newer, "biologic" medication may work best to ease the joint swelling and tenderness of rheumatoid arthritis, a new study finds.

There are many therapies for rheumatoid arthritis, but the newer drugs are not better than older ones when used alone, the report's authors found.

"There are no clinically important differences among the older synthetic drugs or among the newer biologic drugs," said lead researcher Dr. Katrina E. Donahue, an assistant professor in the department of family medicine at the University of North Carolina, Chapel Hill. "There are combination therapies that do work better than using one drug in people not responding to one drug alone," she said.

Combining a synthetic with a biologic appears to work best, Donahue said. However, which combinations are most effective still isn't clear. In addition, the short-term side effects appear to be the same for both types of drugs, she added.

In the study, Donahue's team reviewed 23 published studies that compared the benefits and harms of different rheumatoid arthritis drugs. These included, synthetic disease-modifying antirheumatic drugs (DMARDs), biologic DMARDs, and corticosteroids.

Synthetic DMARDs include hydroxychloroquine (Plaquenil), leflunomide (Arava), methotrexate (Trexall) and sulfasalazine (Azulfidine). Biologic DMARDs include abatacept (Orencia), adalimumab (Humira), anakinra (Kineret), etanercept (Enbrel), infliximab (Remicade) and rituximab (Rituxan). Corticosteroids include drugs such as prednisone.

Donahue's group found that combining methotrexate with a biologic DMARD worked better than methotrexate or a biologic alone. They also found that methotrexate was as effective as the biologics adalimumab and etanercept in early rheumatoid arthritis.

Adalimumab and
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. Use of certain lipid measures not more effective in predicting coronary heart disease
3. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
4. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
5. Stanford study highlights cost-effective method of lowering heart disease risks
6. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
7. Case Management Cost-Effective Way to Cut Heart Risks
8. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
9. Nasal Anthrax Vaccine Proves Effective in Animal Study
10. Family-based treatment more effective than supportive psychotherapy in treating bulimia
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Combos  Effective Against Rheumatoid Arthritis 
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 ... Outlook to 2020” provides company shares and distribution ... and global corporate-level profiles of the key market ... to the Laryngoscopes market wherever available. , The ... market forecast models. Rsearcher uses epidemiology and capital ...
(Date:7/25/2014)... 2014 (HealthDay News) -- Although cervical cancers are declining ... to human papillomavirus (HPV) are increasing, a new study ... base of the tongue and tonsils have increased over ... younger than 45, the Canadian researchers report. "The ... younger men and of anal cancer among younger women ...
(Date:7/25/2014)... July 25, 2014 The Europe Cyber ... market in Europe with analysis and forecast of revenue. ... billion in 2014 to $19.07 billion by 2019, at ... Browse through the TOC of the Europe Cyber Security ... analysis provided. It also provides a glimpse of the ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 The American ... new volunteer network “ABTA CommYOUnity™” during its annual patient ... pivotal time for the brain tumor community as we ... patient and caregiver support services and funding brain tumor ... are passionate about brain tumor awareness and getting our ...
(Date:7/25/2014)... July 25, 2014 Today, nearly 700,000 people ... yet, when it comes to pinpointing causes or risk factors, ... don’t know who, we don’t know when, and we don’t ... MNA, president & CEO, American Brain Tumor Association. “It’s frustrating ... Brain Tumor Association funds research to pursue answers to these ...
Breaking Medicine News(10 mins):Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 4Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 5Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:Brain Tumor Causes and Risk Factors Elude Scientists 2Health News:Brain Tumor Causes and Risk Factors Elude Scientists 3Health News:Brain Tumor Causes and Risk Factors Elude Scientists 4
... is being developed that will create a calendar-like printout ... of Georgia physical therapist and associate dean, who wanted ... ,Multiple prescriptions can be confusing: knowing which pill is ... have special instructions. ,'The idea came ...
... excessive dandruff and it could be treated as an early ... // ,Barry Stevens, founder of the London Trichology Society, ... common among AIDS patients. ,'Seborrhoeic Dermatitis among HIV-positive ... percent among general population,' he said. ,'Though a ...
... Society (WHS) and Blackwell Publishing are excited to announce ... Wounds in a special issue of Wound Repair and ... ,Because of continued interest by the WHS ... Foundation, a proposal was developed to establish guidelines for ...
... this holiday season? It’s one of the biggest fashion trends this ... back, neck and shoulder pain, headaches and possibly even arthritis. // ... headaches and what I usually do is look for their purse ... on the medical staff at Baylor Medical Center at Garland. ...
... a study that affirms the role of partners or ... ,Publishing results in the January issue of Archives of Dermatology, ... for skin examination sessions are bound to take the sessions ... translates to reduced risks of developing the dreaded melanoma or ...
... met his Waterloo twice, the second time proving fatal, at ... from US, Switzerland and Canada have put to rest a ... of the French conqueror. ,The most recent theory, ... of Napoleons’ hair was that the ruler’s death was due ...
Cached Medicine News:Health News:New Software to Help Patients 2Health News:Pair Up-Prevent Melanoma 2Health News:Mighty Conqueror Felled by Stomach Cancer 2
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... , Weltweite Exklusivlizenz ... ermöglicht QIAGEN die Entwicklung von Tests auf ... Blutkrebs  Neuer Test weist Mutationen ... Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten ...
(Date:7/24/2014)... COLUMBUS, Ohio, July 24, 2014  Mettler-Toledo International Inc. ... results for 2014.  Provided below are the highlights: ... in the quarter compared with the prior year. Reported ... currency. , Net earnings per diluted share as ... second quarter of 2013. Adjusted EPS was $2.57, an ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... Therapeutics (Nasdaq: FOLD ) will release its first quarter 2010 financial results ... The results announcement will be followed by a live conference call and webcast ... , , ... 5 p.m. EDT by dialing 877-303-5859 (U.S./ Canada ) or 678-224-7784 ...
... April 27 The U.S. Food and Drug Administration today approved the ... in certain adults. , , , ... ) , , , ... is intended for patients ages 18 and older whose severe and persistent asthma ...
Cached Medicine Technology:Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010 2FDA Approves New Device for Adults with Severe and Persistent Asthma 2FDA Approves New Device for Adults with Severe and Persistent Asthma 3
Performa cemented stem....
M2 cemented hip stem....
Porous foundation 480 series....
Cemented foundation 460 series....
Medicine Products: